School of Advanced Nutritional and Medical Research

Cancer Recurrence Prevention Procedure

Author: Tsuneo Kobayashi MD, PhD
Institution: IMHC clinic
Address: 7-9-3 Asakusa Taitouku Tokyo Japan
E-mail address: ft1992 (at) vega.ocn.ne.jp

ABSTRACT
We have exploited sensitive tumor marker combination assay (TMCA). This method was obtained 87.5% sensitivity for early lung and colon cancer patients in a double blind test (1988) with the collaboration of Mayo Clinic and NCI in USA. With utilizing this method, we can classify postoperative cancer patient into risk assessment according to the natural history of cancer. High risk postoperative patient should be treated by counter-measure of cancer recurrence prevention program which are including herbal medicine, detoxification therapy and systemic hyperthermia. Our tumor marker combination assay is composed of specific tumor marker, associated tumor marker and growth related tumor marker. We have exploited complex tumor marker so as to discriminate cancer and healthy resident from the computer analysis. With these combination, our TMCA has high sensitivity and high specificity.
With these methods, I could succeed cancer recurrence prevention in 104 postoperative patients.

Cancer recurrence prevention procedure
70% of cancer sacrifices are suffered from recurrence cancer. Muto professor in Tokyo University officially stated that Tokyo University, Japanese NCI and Cancer research center Hospital cannot treat recurrence cancer. Some medical doctors said that cancer became the treatable disease because 5 year survival rate are prolonged in gastric cancer, colon cancer and prostate cancer, but on the other hand, 5 year survival rate of lung cancer, ovarial cancer are not elevated.
Japanese Health and Welfare minister aim to elevate 20% of 5 year survival rate on the 10 year anticancer national program. Why this kind of disastrous medicine continue in Japan? I am regrettable because I have engaged in cancer prevention program among 20000 subjects and I have succeeded in cancer prevention program in 99% successful rate. I have carried out cancer recurrence program among about 1000 subjects with 96% successful rate and furthermore, I have treated about 5000 patients who have given up from other hospital. As to this, medical journalists who are related with Kyoto University, have reported 10 years ago that 5 year’s survival rate in our hospital is 70% in weekly journal according to my hospital investigation for 6 months. One month later,Health and Welfare minister bothered our hospital running and asked to me that I should back the permission of national insurance to Health and Welfare minister. And they said that it is no problem which our hospital carry out good medicine or not, but they are against that my hospital deviated from national insurance regulation. If I don’t give up the permission of national insurance, they threatened to retrench our national insurance. After 5 years, the court judged that this mixed consultation regulation rule is against Japanese constitution.

1. Recurrence prevention procedure
a) Consideration from natural history of cancer
From authorized medicine, first, image diagnosis by CT and MRI and secondary, biopsy and finally pathological diagnosis under microscope. So object of biopsy is over 1 cm diameter. In the case of difficult place by biopsy, diagnosis can be made after 2-3 cm diameter tumor grown up. About these secondary cancer prevention, Baylor professor in Harvard University reported that secondary cancer prevention never decrease cancer sacrifice rate 25 years ago. The prolongation of 5 year survival rate is only deviation of statistics. In Japan, medical doctor adhered to the treatment of surgical operation,radiation therapy and chemotherapy and the number of cancer sacrifices are increasing. Every year, 10000 people sacrificed are increasing in Japan. In the USA, government is engaged in primary cancer prevention and cancer sacrifices are decreasing in number, but in Japan, if medical doctor don’t start cancer recurrence prevention program, cancer sacrifices never decrease. As for cancer recurrence prevention, image diagnosis never cope with cancer recurrence prevention, so we exploited 100 time more sensitive tumor marker combination assay (TMCA) in behalf of cancer recurrence prevention program. We will state in section (). This method is 5 risk assessment classification by TMCA. As for higher risk group, we can treat appropriate method so as to reduce risk assessment.

b) Upper postoperative patient 68 years old male after colorectomy. His medical doctor said that there are high susceptible to recurrence of cancer. So he received TMCA so as to avoid recurrence of cancer. His risk assessment is tumor stage IV(TSIV) which is just before cancer appearance. He carried out 4 times of detoxification refreshment therapy. He continued lower risk group classification for 4 years. When he had experienced 2 times of high risk assessment (Dec. 1989, March 1993), he carried out combination treatment of herbal medicine(SA) and detoxification therapy. By these procedure, the risk assessment became to lower risk assessment and he had succeeded to avoid recurrence opportunity. He can get cancer recurrence prevention program for 12 years. So he could successfully suppress cancer recurrence for 12 years.

c) If medical doctor can utilize this TMCA, all doctor can carry out cancer recurrence prevention program. After risk assessment of TMCA, you should treat the patient according to the risk classification by holistic treatment which is demonstrated under the chart.

d) Achievement
Under figure showed the statistics among 104 cancer recurrence candidate subjects who are
carried out cancer recurrence method up to 2nd step. 7.7% of subjects are classified into
aggravating tendency. If there is no better effect by holistic treatment, you should finally carry
out systemic hyperthermia , then you can get good result.

2. What cancer is?
Up to now,many theory are proposed, but fundamentally the theory of Virchow is predominant in the world which cancer appear by mutation and cancer continue to grow up to die. These theory was believed by many medical doctors. This theory is very beneficial for surgical operation and radiation therapy and chemotherapy. These 3 authorized treatment and mutation theory are compensated each other. Now we proceed to look for the essence of cancer.

a) The map of gastric cancer in China shows that cancer is made from food eating habits and clearly demonstrated that cancer is district disease.

b) From the relocation data, When Japanese relocate to California, gastric cancer decrease 30%, colon cancer increase 30% and prostate cancer increase 3 times more. These data show that cancer develop from food eating habit, not mutation. Of course, there is possibility that carcinogenic substances contained in meat eating.

c) Cancer is neoplasm made by human-being. Fundamentally, not foreign matter, but made from long food and life style habits.
Cancer is not only mutated cell which was insisted by Virchow 160 years ago, but normal cell are changed by evil doing of man-kind, for example, intake of carcinogen or food and life style which is not appropriate for man-kind body, produced aggravation of internal circumstances and persecuting normal cell into cancer cells. Cancer cells are only persecuted by mankind and derived from normal cells. Virchow’s mutation theory is clearly wrong understandings from field cancerization and the data of redifferentiation. Cancer is just like of delinquent boys and girls in your family.
i) In real situation, neoplasm tissue are composed of cancer cell, interstitial tissue and cancer vessels as if fetus are composed of fetus itself , placenta and chorion. Therefore, cancer tissue composed of cancer cells, cancer interstitial tissue and cancer vessels, each of them are respectively, produce cancer specific tumor marker(s-TM), cancer associated tumor marker(a-TM) and cancer vessels information (growth related tumor marker, g-TM).
Therefore, we must investigate 3 type of tumor marker so as to grasp cancer tissue. If you measure only specific tumor markers, you cannot grasp cancer tissue only with under 20% reliability.
ii) Especially, in the case of undifferentiated cancer and sarcoma, they don’t produce specific tumor marker, so you will easily lose the existence of cancer only with utilization of s-TM. As cancer is not foreign cell, so immunotherapy is effective only with 20%.

d)
i) If cancer cell were delinquent cell, cancer cell can be estimated to redifferentiate to normal cell with the addition of appropriate cytokine, appropriate temperature and oxygen content
ii) On the other hand, the phenomenon that the reduction of mitochondrial number and shrinkage of mitochondoria was reported 50 years ago in the processing of the carcinogenesis. This important phenomenon was neglected for 50 years before the molecular biology become conspicuous. I have found 10 years before that apoptosis become difficult if mitochondria damaged by carcinogen and become difficult to produce cytochrome C. As nuclear DNA in which nucleus has nuclear membrane and poly ADP as 3rd DNA and has a difficulty to receive the damage of carcinogen in comparison with mitochondria which has no nuclear membrane. So mitochondrial DNA is fragile 10 time more than nuclear DNA. In this consideration, mitochondrial damage is the most important factor in the processing of carcinogenesis.
iii) So the way of thinking that cancer was happened by mutation, is wrong. As in the processing of carcinogenesis, not only cancer cell, but also the carcinogenesis of interstitial cell and cancer vessels have happened. So called of field cancerization is suitable. From these consideration of field cancerization , carcinogen produce the damage of mitochondria of cancer cell and interstitial cell and vessels at first. And secondary the carcinogenesis of cancer,interstitial cell and cancer vessels will happen. So these field cancerization has most appropriate explanation. It is difficult for us to think that after cancer developed by DNA mutation, cancer cell produce interstitial tissue and cancer vessels. As Otto Warburg explained fundamentals of carcinogenesis which is the change that aerobic cell become to anaerobic cell. In this meaning the most important change from cancer cell to normal cell is the improvement of mitochondria.
Next photograph is reported from professor Odajima in Kanazawa University 20 years ago. Hepatoma cell redifferentiated to normal liver cell by the addition of panax ginseng (50 microgram saponin). In the next electron microscopic examination revealed that diminished and shrunk mitochodoria became to normal mitochondoria and anaerobic cell changed into aerobic cell. This is reasonable from the consideration that the differentiation of organ was determined by the number and shape of the mitochondoria.
So the essence of carcinogenesis is that normal cell was changed by carcinogen and mitochondoria to be shrunk and to become in difficulty in apoptosis and to become undifferentiated cell. In this meaning the restoration of mitochondoria is important in the treatment of cancer. In this restoration of mitochondoria, appropriate temperature, cAMP, HSP, calcium content and adequate oxygen content are important.

3. Necessary technique for cancer recurrence prevention

a) First condition so as to grasp correctly the cancer tissue by blood examination.
Cancer tissue are composed of cancer cell, cancer interstitial cell and cancer vessels.
So if you want to grasp cancer tissue correctly, you must examine s-TM, a-TM and g-TM so as to combine. Otherwise new method,biochemical biopsy is necessary.

b) How to conquer the problem of tumor marker?
i) There are many problems about the tumor marker. When you want to elevate sensitivity with single tumor marker, the specificity will decrease. It is impossible to solve this problem withsingle tumor marker.. So we must use complex tumor marker, for example, e/Fe, CEAx TPA, CEAxTPA/ FT/Fe which is obtained by computer calculation. If you use complex tumor marker which is demonstrated in the next table, you can elevate both of sensitivity and specificity.

ii) Furthermore, we utilize multivariate analysis formula. As to the multivariate analysis formula about ALP isoenzyme as follows.
Z = 125APA + 0.6xALP1- ALP2/3 – 17.5
Z1 = 1.499 x JZ + 2.03x log RNaseTPA – 16.789
Z2= 1.430x JZ1 + 2.03 xlogRNase + 1.631xlogTPA- 16.789
By the application of Z2 formula, we can get sensitivity 84.5%, specificity 84.5%, accuracy 84.5%.
White circle shows normal resident and black circle shows cancer patient.

c)Malignant cancer don’t produce specific tumor marker, so it is very dangerous to diagnosis with only specific tumor marker. Furthermore, as pathological diagnosis determine the final diagnosis, but in some places, it is difficult to take biopsy. In this meaning, we must utilize biochemical biopsy so as to analysis of isoenzyme. Next chart is the typical example of biochemical biopsy in ALP isoenzyme. Next chart is the typical example of biochemical biopsy. We can grasp the activity of cancer tissue utilizing this concept.
Next chart demonstrate the process of esophageal cancer patient for 7 months. The number are parameter of ALP isozyme, ALP1, ALP2/3, APA. According to the aggravation of esophageal cancer, ALP1,ALP2/3, APA are increased with CEA increasing. So according to the aggravation of cancer, ALP1, ALP2/3, APA are become to good marker.

CONCLUSION
I have succeed in cancer risk assessment by tumor maker combination assay(TMCA) with complex tumor marker and multivariate analysis. By this risk assessment, improvement of high risk group was obtained with the counter-measurement of cancer recurrence prevention including detoxification therapy, herbal medicine (SA) and hyperthermia. The success rate was obtained with 93-100%. With this method, I have succeeded in cancer recurrence prevention in 104 postoperative patients.

REFERENCES
(1) Schor. S.L., et al. J. Cell Sci.,73:221,1985
(2) Sakakura T. et al.: J. Natl. Cancer Inst. 66:953, 1981
(3) Mackie E. et al: Proc. Natl. Acad. Sci. USA, 84:4621,1987
(4) O. Warburg. Science, 124-269, 1956
(5) Gimbrone, M et al. Tumor dormancy in vivo by prevention of neovascularization. J. Exp Med. 136:261-276, 1972
(6) Folkman,J: Tumor angiogenesis. Adv.Cancer Res. 19: 331-358, 1974
(7) Lewis, W.H. The vascular patterns of tumors Bull. John Hopkins Hosp. 41:156-162,1927
(8) Bierman, H.R. et al: Studies on the blood supply of tumor in man. IV. The increased oxygen content of venous blood draining neoplasm. J. Natl. Cancer Inst. 12:701-707, 1952
(9) Kobayashi T. et al: prospective Investigation of tumor markers and Risk assessment in early cancer screening. Cancer. 73: 1946-1953,1994
(10) Sugimoto k. et al: The effects of the anticancer herbal medicine(Sun Advance) in mice. Proc. Symp. WAKAN-YAKU 15: 224, 1982
(11) Tanimizu t. et al.: New Approach to Chinese Herb Medicine: Inhibition by Herb medicine” Sun Advance “ of SV40-virus transformation in mouse cells. Proc. Symph. WAKAN-YAKU, 15:228, 1982 (12) Hayashida. S et al.: Effect of BRM-induced systemic Hyperthermia combined with Immunochemotherapy on advanced breast cancer with metastasis: 5th Inter. Symp. On Hyperthermic oncology, 361, 1987
(13) Takeda et al.: Effect of BRM-induced systemic Hyperthermia combined with Immunochemotherapy on metastatic testicular cancer. 5th Inter. Symph. On Hyperthermic Oncology,369,1987
(14) Kobayashi T et al.: Cancer diagnosis by means of Ryodoraku neurometric Ptterns. Amer. J. Acupuncture 1: 305-312,1984
(15) Kobayashi T.: Early diagnosis of microcancer by cancer check of related acupuncture meridian, 12:63-68, 1985
(16) Kobayashi T.: The detection and treatment of microcancer. Amer. J. Acupunctutre, 12: 137-147,1985
(17) Kobayashi T. Cancer Patient Differences between right and left sides determined with Ryodoraku Acupuncture. Amer. J. Acupuncture 12: 241-245,1985
(18) Kobayashi T.: Relationships between Ryodorku autonomic nervous patterns and immunological levels. 12: 23-28,1985
(19) Kobayashi T.: The significance of acupuncture meridian abnormalities specific to cancer 12: 139-142, 1986
(20) Joya,C., Orrenius, S. Mitochondoria, oxygen metabolism and the regulation of cell death. International Congress Series 1233:259-272,2000